5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1

被引:11
|
作者
Zhang, Yurou [1 ]
Fu, Qinghua [1 ]
Wu, Tian [1 ]
Liu, Kang [1 ]
Xiao, Yang [1 ]
Liao, Qichao [1 ]
Qi, Xinyi [1 ]
Li, Yixing [1 ]
Zhou, Lei [1 ]
机构
[1] Guangxi Univ, Coll Anim Sci & Technol, State Key Lab Conservat & Utilizat Subtrop Agrobio, Nanning 530004, Peoples R China
基金
中国国家自然科学基金;
关键词
5-Methoxyflavone; NAFLD; Oxidative stress; IN-VIVO; FLAVONOIDS; OBESITY; STRESS; GENES; MICE;
D O I
10.1016/j.freeradbiomed.2022.12.093
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent liver disease that is closely related to obesity and metabolic disorders. 5-methoxyflavone (5-MF) is a flavonoid with DNA polymerase-8 inhibitory properties. In this study, we explored the effects of 5-MF on NAFLD and its potential mechanisms using oleic acid/palmitic acid-treated HepG2 cells and high-fat diet-fed C57BL/6J mice. Our results showed that 5-MF not only alleviated fat deposition and hepatic steatosis, but also improved oxidative damage. In addition, 5-MF has the effect of alleviating disorders of glucose metabolism and enhancing energy expenditure in HFD-induced obese mice. Mechanistically, reverse screening methods and molecular docking analysis were used in combination, and revealed that cytochrome P450 1A1 (CYP1A1) is the target for 5-MF. Further experiments showed that 5-MF ameliorated triglycerides deposition by inhibiting the enzyme activity and protein expression of CYP1A1. In conclusion, 5-MF provides a novel strategy for the prevention and treatment of high-fat-induced NAFLD.
引用
收藏
页码:178 / 191
页数:14
相关论文
共 50 条
  • [41] Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1)
    Wu, Mengyao
    Lo, Tak-Ho
    Li, Liping
    Sun, Jia
    Deng, Chujun
    Chan, Ka-Ying
    Li, Xiang
    Yeh, Steve Ting-Yuan
    Lee, Jimmy Tsz Hang
    Lui, Pauline Po Yee
    Xu, Aimin
    Wong, Chi-Ming
    ELIFE, 2023, 12
  • [42] Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis
    Abdelmegeed, Mohamed A.
    Banerjee, Atrayee
    Yoo, Seong-Ho
    Jang, Sehwan
    Gonzalez, Frank J.
    Song, Byoung-Joon
    JOURNAL OF HEPATOLOGY, 2012, 57 (04) : 860 - 866
  • [43] Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications
    Barouki, R
    Morel, Y
    BIOCHEMICAL PHARMACOLOGY, 2001, 61 (05) : 511 - 516
  • [44] Omentin-1 mitigates non-alcoholic fatty liver disease by preserving autophagy through AMPKα/mTOR signaling pathway
    Huang, Ziqing
    Luo, Linfei
    Xiao, Zhihua
    Xiong, Ming
    Wen, Zhili
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4
    Huang, Lu
    Ding, Wei
    Wang, Ming-Qiang
    Wang, Zheng-Gen
    Chen, Hong-Hui
    Chen, Wen
    Yang, Qiong
    Lu, Ting-Na
    Yang, Qing
    He, Ji-Man
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (10) : 5239 - 5255
  • [46] Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease
    Valenzuela, Rodrigo
    Ortiz, Macarena
    Catalina Hernandez-Rodas, Maria
    Echeverria, Francisca
    Videla, Luis Alberto
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (31) : 5250 - 5272
  • [47] Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity
    Knockaert, Laetitia
    Fromenty, Bernard
    Robin, Marie-Anne
    FEBS JOURNAL, 2011, 278 (22) : 4252 - 4260
  • [48] Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
    Jamwal, Rohitash
    Barlock, Benjamin J.
    PHARMACEUTICALS, 2020, 13 (09) : 1 - 15
  • [49] Cytochrome P450 2E1 and its roles in disease
    Guengerich, F. Peter
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 322
  • [50] Genetic Variations of AKT1 are Associated with Risk Screening for Non-Alcoholic Fatty Liver Disease
    Ding, Yajie
    Tang, Zongzhe
    Zhang, Ru
    Zhang, Mengting
    Guan, Qing
    Zhang, Liuxin
    Wang, Hongliang
    Chen, Yue
    Zhang, Wei
    Wang, Jie
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 1365 - 1376